Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SGEN

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

StockNews.com

Buy, Sell, or Hold: Pfizer Inc. (PFE)

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

StockNews.com

2 Robinhood Stocks to Buy and Hold Forever

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

The Smartest Stock to Buy for Under $50 Now

Pharma giant Pfizer (PFE) had a successful fiscal year 2022 with record-breaking revenue and earnings. Moreover, its recent acquisition should boost its portfolio and revenue. Given the market volatility, this fundamentally strong stock might be an ideal buy for under $50. Keep reading.

StockNews.com

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Check Out What Whales Are Doing With SGEN

A whale with a lot of money to spend has taken a noticeably bullish stance on Seagen. Looking at options history for Seagen (NASDAQ:SGEN) we detected 10 strange trades.

Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,400 Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 18.41% on an annualized basis producing an average annual return of 27.81%. Currently, Seagen has a market capitalization of $32.98 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

Benzinga

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Merck & Co Inc (NYSE:MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that the deal could be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to…

Benzinga

Where Seagen Stands With Analysts

Analysts have provided the following ratings for Seagen (NASDAQ:SGEN) within the last quarter:

Benzinga

SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).

Benzinga

Merck Shows Takeover Interest In Seagen: WSJ

Merck & Co Inc (NYSE:MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ:SGEN), Wall Street Journal reported citing people familiar with the matter. If the deal happens, it would be significant, given Seagen's market value of roughly $28 billion. According to the report, some people said other unnamed suitors are also eying Seagen, a…

Benzinga

$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 12.54% on an annualized basis producing an average annual return of 19.38%. Currently, Seagen has a market capitalization of $26.91 billion.

Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 5.77% on an annualized basis producing an average annual return of 17.01%. Currently, Seagen has a market capitalization of $26.17 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Seagen Inc (NASDAQ:SGEN) announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY). Data from this trial will form the basis of a planned supplemental…

Benzinga

Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence

The Board of Directors of Seagen Inc (NASDAQ:SGEN) announced that its long-time president, CEO, and chairman Clay Siegall, is on a leave of absence. The move follows an alleged incident of domestic violence. While Siegall, who informed the company that he's in the middle of a divorce, denied those allegations. The Seagen board…

Benzinga

Looking Into Seattle Genetics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Seattle Genetics (NASDAQ:SGEN) posted sales of $426.46 million. Earnings were up 21.84%, but Seattle Genetics still reported an overall loss of $136.49 million.

Benzinga

Expert Ratings for Seagen

Within the last quarter, Seagen (NASDAQ:SGEN) has observed the following analyst ratings:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Read Why This Analyst Is 'Encouraged' By Seagen's Q1 Sales

Following Seagen Inc's (NASDAQ: SGEN) 1Q22 earnings release, RBC Capital Markets is encouraged by the quarterly sales of the product portfolio in light of previously set cautious guidance.

Benzinga

Recap: Seagen Q1 Earnings

Seagen (NASDAQ:SGEN) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by 26.0%, reporting an EPS of $-0.74 versus an estimate of $-1.0.

Benzinga

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing…

Benzinga

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF)

Benzinga

What 7 Analyst Ratings Have To Say About Seagen

Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter:

Benzinga

Looking Into Seattle Genetics's Return On Capital Employed

According to data from Benzinga Pro, during Q4, Seattle Genetics's (NASDAQ:SGEN) reported sales totaled $429.85 million. Despite a 40.57% increase in earnings, the company posted a loss of $174.63 million.

Benzinga

Why Are Seagen Shares Sinking Today?

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

1 2

People

Kritika SarmahHer

727 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.